Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy Combined With ADC (MRG003) for Induction Conversion Therapy to Downstage Primary Stage IVB Oral/Oropharyngeal Squamous Cell Carcinoma：An Exploratory Two-Arm Randomized Controlled Trial (Transforming Trial)

NCT07844551 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT07844551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy Combined With ADC (MRG003) for Induction Conversion Therapy to Downstage Primary Stage IVB Oral/Oropharyngeal Squamous Cell Carcinoma：An Exploratory Two-Arm Randomized Controlled Trial (Transforming Trial)
Lead sponsor
Huashan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 20, 2026
Completion date
December 30, 2030
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage ivb oral cavity squamous cell carcinoma, stage ivb oropharyngeal (p16-negative) carcinoma ajcc v8